GHRH 类似物 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
== DPP-4 mechanism == Fig.1: During a meal, the incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent gastric inhibitory polypeptide (GIP) are released by the small intestine into the blood stream. These hormones regulate insulin secretion in a glucose-dependent manner. (GLP-1 has many roles in the human body. It stimulates insulin biosynthesis, inhibits glucagon secretion, slows gastric emptying, reduces appetite and stimulates regeneration of islet β-cells.) GLP-1 and GIP have extremely short plasma half-lives due to very rapid inactivation, catalyzed by the enzyme DPP-4. Inhibition of DPP-4 slows their inactivation, thereby potentiating their action, leading to lower plasma glucose levels, hence its utility in the treatment of type 2 diabetes. (Figure 1).
Electron-capture dissociation (ECD) — A mass spectrometry fragmentation technique for sequencing proteins and peptides. Isotopic resonance hypothesis — Proposes that specific isotopic compositions can accelerate biochemical reactions. Experimental studies on Escherichia coli growth have supported aspects of the hypothesis. Proteomics and biomarkers — Discovery of proteomic signatures in neurodegenerative diseases such as Alzheimer’s disease, along with developments in immunoproteomics and molecular biometry. Origin of life experiments — Research showing that abiotically synthesized mixtures, such as those produced in Miller–Urey type experiments, can sustain bacterial growth.
== Release == Valve announced Half-Life: Alyx in November 2019. They waited until it was almost complete before announcing it, aiming to avoid the delays of previous games. They were conscious that players, having waited years for a new Half-Life game, might be disappointed by a VR game, and tightly managed the announcement. To promote Alyx, Valve made the prior Half-Life games free on Steam from January 2020 until its release. Valve was due to showcase Alyx at the 2019 Game Awards that December, but canceled hours prior, saying they were "hard at work on the game". Alyx was released on March 23, 2020. It was free to owners of Valve Index headsets or controllers. Valve released a Linux version on May 15, along with Vulkan rendering support for both platforms. A pre-release build was mistakenly released on Steam; it included non-VR developer tools, allowing interactions such as picking up objects and firing weapons. However, most basic interactions, such as pressing buttons or filling Alyx's backpack, could not be completed with mouse-and-keyboard controls. Asked about plans for future Half-Life games, the designer David Speyrer said Valve was willing but were waiting for the reaction to Alyx. Walker said "we absolutely see Half-Life: Alyx as our return to this world, not the end of it". Alyx is included with all Steam Frame headsets, a standalone VR headset released by Valve in September 2026. Valve ported Alyx to run on the Steam Frame's ARM64 processor and optimized it with foveated rendering, whereby resolution is reduced in areas the player is not looking at.
Excessive amounts of valproic acid can result in somnolence, tremor, stupor, respiratory depression, coma, metabolic acidosis, and death. In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/L during controlled therapy, but may reach 150–1500 mg/L following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography. In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (pKa of 4.9). In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body. Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored. Supplemental L-carnitine is indicated in patients having an acute overdose and also prophylactically in high risk patients. Acetyl-L-carnitine lowers hyperammonemia less markedly than L-carnitine.
=== opal or umber mutations (UGA) === The third and last stop codon in the standard genetic code was discovered soon after, and corresponds to the nucleotide triplet "UGA". To continue matching with the theme of colored minerals, the third nonsense codon came to be known as "opal", which is a type of silica showing a variety of colors. Nonsense mutations that created this premature stop codon were later called opal mutations or umber mutations.
Sources: en.wikipedia.org
Within a year he was backtracking, announcing that sharia was inappropriate for the Jamahiriya because it guaranteed the protection of private property, contravening The Green Book's socialism. His emphasis on placing his own work on a par with the Qur'an led conservative clerics to accuse him of shirk, furthering their opposition to his regime. In July 1977, a border war broke out with Egypt, in which the Egyptians defeated Libya despite their technological inferiority. The conflict lasted one week before both sides agreed to sign a peace treaty that was brokered by several Arab states. Both Egypt and Sudan had aligned themselves with the US, and this pushed Libya into a strategic, although not political, alignment with the Soviet Union. In recognition of the growing commercial relationship between Libya and the Soviets, Gaddafi was invited to visit Moscow in December 1976; there, he entered talks with Leonid Brezhnev. In August 1977, he visited Yugoslavia, where he met its leader Josip Broz Tito, with whom he had a much warmer relationship. He also enjoyed a warm relationship with Romanian leader Nicolae Ceaușescu. According to Romanian spy chief Ion Mihai Pacepa, Gaddafi once exclaimed to Ceaușescu, "My brother! You are my brother for the rest of my life!" After Pacepa defected to the US in July 1978, Gaddafi and Yasser Arafat contributed $1 million each to Ceaușescu's $4 million bounty on Pacepa.
=== Ka–Ke === Henrik Kacser FRSE (1918–1995). British geneticist and biochemist at Edinburgh, founder of metabolic control analysis. Emil T. Kaiser (1938–1988). Hungarian-born American protein chemist at the University of Chicago, known for his work on enzyme modification. Member Natl. Acad. Sci. USA. Herman Kalckar (1908–1991). Danish biochemist at the New York Public Health Research Institute, who worked on cellular respiration, nucleotide metabolism and galactose metabolism. Member Natl. Acad. Sci. USA Nathan O. Kaplan (1917–1986) Enzymologist at UC San Diego, founding editor of Methods in Enzymology. Member Natl. Acad. Sci. USA Sir Bernard Katz FRS (1911–2003). German-British neuroscientist and biophysicist at University College London. Nobel Prize in Physiology or Medicine (1970) for work on nerve biochemistry and the pineal gland. Stuart Alan Kauffman (b. 1939). American theoretical biologist, expert on complex systems, now at the University of Pennsylvania. Fellow of the Royal Society of Canada. Douglas Kell (b. 1953). British biochemist at the University of Manchester, known for research on functional genomics, metabolomics and the yeast genome. John Kendrew FRS (1917–1997). British x-ray crystallographer at the European Molecular Biology Laboratory, Heidelberg, known for determining the crystal structure of myoglobin. Nobel Prize in Chemistry (1962). Sir Ernest Kennaway FRS (1881–1958), British pathologist at the Institute of Cancer Research, London, who carried out early work on carcinogenic effects of hydrocarbons. Eugene P.
In January 2016, Kardashian hosted the Kocktails with Khloé pop culture–themed variety talk show, which aired on the FYI cable channel. The show was cancelled after 14 episodes. Kardashian and business woman Emma Grede launched their clothing line Good American in the same year, and made $1 million in sales on the first day. Good American started by selling jeans ranging from size 00 to 24 and has expanded to a variety of clothes including workout clothes, dresses and a maternity collection. Kardashian starred and produced Revenge Body with Khloé Kardashian, an American reality television series that premiered on the E! cable network, on January 12, 2017.
In November 2007, Merck agreed to pay $4.85 billion to settle most of the pending Vioxx lawsuits. The settlement required that claimants provide medical and pharmacy records confirming the occurrence of a heart attack, ischemic stroke, or sudden cardiac death; the receipt of at least 30 Vioxx pills within 60 days prior to the injury or death; and confirmation of Vioxx being used within 14 days of the Vioxx-related event. The settlement was generally viewed by industry analysts and investors as a victory for Merck, considering that original estimates of Merck's liability reached between $10 billion and $25 billion. As of mid-2008, when the plaintiff class had reached the threshold percentage required by Merck to go through with the settlement, plaintiffs had prevailed in only three of the twenty cases that had reached juries, all with relatively small awards. Merck has refused to consider compensation for Vioxx victims and their families outside the US. This is particularly true in the UK where there are at least 400 victims and the legal protection afforded to the victims and their families is particularly weak. According to internal e-mail traffic released at a later lawsuit, Merck had a list of doctors critical of Vioxx to be "neutralized" or "discredited". "We may need to seek them out and destroy them where they live," wrote an employee. A Stanford Medical School professor said that Merck was engaged in intimidation of researchers and infringement upon academic freedom.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽，它难以通过胃肠道吸收，通常需要注射给药。口服会因消化酶降解而失去活性，因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.